Urologix, Inc. reported unaudited earnings results for the fourth quarter and year ended June 30, 2013. For the quarter, the company reported sales of $4.184 million compared to $4.497 million a year ago. Operating loss was $1.282 million compared to $1.087 million a year ago. Loss before income taxes was $1.281 million compared to $1.208 million a year ago. Net loss was $1.247 million or $0.06 per basic and diluted share compared to $1.225 million or $0.08 per basic and diluted share a year ago. The year-over-year decline in revenue was driven by a low single-digit decline in sales of CTT and low double-digit declines in sales of Prostiva compared to the prior year.

For the year, the company reported sales of $16.590 million compared to $17.027 million a year ago. Operating loss was $3.922 million compared to $4.145 million a year ago. Loss before income taxes was $4.278 million compared to $4.640 million a year ago. Net loss was $4.292 million or $0.21 per basic and diluted share compared to $4.695 million or $0.32 per basic and diluted share a year ago. Net cash used for operating activities was $1.959 million compared to $0.713 million a year ago. Purchases of property and equipment were $79,000 compared to $57,000 a year ago. The year-over-year decline in revenue was driven by a mid-single-digit decline in sales of Cooled ThermoTherapy(TM) (CTT) products and a mid-single-digit increase in sales of Prostiva(R) Radio Frequency (RF) Therapy products.

For the fiscal year 2014, the company expects revenue in the range of $15 million to $17 million.

For the fourth quarter ended June 30, 2013, the company reported impairment of identifiable intangible assets of $160,000.